Federal Register / Vol. 72, No. 87 / Monday, May 7, 2007 / Notices 25767 

Council, we are seeking individuals 

who are distinguished: (1) In the 

conduct of research, demonstration 

projects, and evaluations with respect to 

health care; (2) in the fields of health 

care quality research or health care 

improvement; (3) in the practice of 

medicine; (4) in other health 

professions; (5) in representing the 

private health care sector (including 

health plans, providers, purchasers) or 

administrators of health care delivery 

systems; (6) in the fields of health care 

economics, information systems, law, 

ethics, business, or public policy; and, 

(7) in representing the interests of 

patients and consumers of health care. 

Individuals are particularly sought with 

experience and success in activities 

specified in the summary above. 

DATES: Nominations should be received 

on or before June 15, 2007. 

ADDRESSES: Nominations should be sent 

to Ms. Deborah Queenan, AHRQ, 540 

Gaither Road, Room 3238, Rockville, 

Maryland 20850. Nominations also may 

be faxed to (301) 427–1341. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Deborah Queenan, AHRQ, at (301) 427–

1330. 

SUPPLEMENTARY INFORMATION: 42 U.S.C. 

299c, section 931, of the PHS Act, 

provides that the National Advisory 

Council for Healthcare Research and 

Quality shall consist of 21 appropriately 

qualified representatives of the public 

appointed by the Secretary of Health 

and Human Services and, in addition, 

ex officio representatives from other 

Federal agencies specified in the 

authorizing legislation, principally 

agencies that conduct or support health 

care research, as well as Federal officials 

the Secretary may consider appropriate. 

The Council meets in the Washington, 

DC., metropolitan area, generally in 

Rockville, Maryland, approximately 

three times a year to provide broad 

guidance to the Secretary and AHRQ’s 

Director on the direction of and 

programs undertaken by AHRQ. 

Seven individuals will be selected 

presently by the Secretary to serve on 

the Council beginning with the meeting 

in the spring of 2008. Members 

generally serve 3-year terms. 

Appointments are staggered to permit 

an orderly rotation of membership. 

Interested persons may nominate one 

or more qualified persons for 

membership on the Council. Selfnominations are accepted. Nominations 

shall include: (1) A copy of the 

nominee’s resume or curriculum vitae; 

and (2) a statement that the nominee is 

willing to serve as a member of the 

Council. Selected candidates will be 

asked to provide detailed information 

concerning their financial interests, 

consultant positions and research grants 

and contracts, to permit evaluation of 

possible sources of conflict of interest. 

The Department seeks a broad 

geographic representation and has 

special interest in assuring that women, 

minority groups, and the physically 

handicapped are adequately represented 

on advisory bodies, and therefore, 

particularly encourages nominations for 

appropriately qualified female, 

minority, and/or physically 

handicapped candidates. 

Dated: April 26, 2007. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 07–2239 Filed 5–4–07; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Healthcare Research and 

Quality Notice of Meeting 

In accordance with section 10(d) of 

the Federal Advisory Committee Act (5 

U.S.C., Appendix 2), announcement is 

made of a Health Care Policy and 

Research Special Emphasis Panel (SEP) 

meeting. 

A Special Emphasis Panel is group of 

experts in fields related to health care 

research who are invited by the Agency 

for Healthcare Research and Quality 

(AHRQ), and agree to be available, to 

conduct on an as needed basis, 

scientific reviews of applications for 

AHRQ support. Individual members of 

the Panel do not attend regularlyscheduled meetings and do not serve for 

fixed terms or a long period of time. 

Rather, they are asked to participate in 

particular review meetings which 

require their type of expertise. 

Substantial segments of the upcoming 

SEP meeting listed below will be closed 

to the public in accordance with the 

Federal Advisory Committee Act, 

section 10(d) of 5 U.S.C., Appendix 2 

and 5 U.S.C. 552b(c)(6). Grant 

applications for ‘‘Ambulatory Care 

Patient Safety Proactive Risk 

Assessment (P20),’’ are to be reviewed 

and discussed at this meeting. These 

discussions are likely to reveal personal 

information concerning individuals 

associated with the applications. This 

information is exempt from mandatory 

disclosure under the above-cited 

statutes. 

SEP Meeting on: Ambulatory Care Patient 

Safety Proactive Risk Assessment (P20). 

Date: May 21–22, 2007 (Open on May 21 

from 8 a.m. to 8:15 a.m. and closed for the 

remainder of the meeting). 

Place: John M. Eisenberg Building, AHRQ 

Conference Center, 540 Gaither Road, 

Rockville, Maryland 20850. 

Contact Person: Anyone wishing to obtain 

a roster of members, agenda or minutes of the 

non-confidential portions of this meeting 

should contact Mrs. Bonnie Campbell, 

Committee Management Officer, Office of 

Extramural Research, Education and Priority 

Populations, AHRQ, 540 Gaither Road, Room 

2038, Rockville, Maryland 20850, Telephone 

(301) 427–1554. 

Agenda items for this meeting are subject 

to change as priorities dictate. 

Dated: April 23, 2007. 

Carolyn M. Clancy, 

Director. 

[FR Doc. 07–2238 Filed 5–2–07; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Pediatric Oncology Subcommittee of 

the Oncologic Drugs Advisory 

Committee; Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting is open to the 

public. 

Name of Committee: Pediatric 

Oncology Subcommittee of the 

Oncologic Drugs Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on June 27, 2007, from 8 a.m. to 4 

p.m. 

Location: Food and Drug 

Administration, Center for Drug 

Evaluation and Research Advisory 

Committee Conference Room, rm. 1066, 

5630 Fishers Lane, Rockville, MD. 

Contact Person: Mimi Phan, Center 

for Drug Evaluation and Research (HFD–

21), Food and Drug Administration, 

5600 Fishers Lane, (for express delivery, 

5630 Fishers Lane, rm. 1093), Rockville, 

MD 20857, 301–827–7001, FAX: 301–

827–6776, e-mail: 

Mimi.Phan@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512542. Please call the Information 

Line for up-to-date information on this 

meeting. 

Agenda: The subcommittee will do 

the following: (1) Discuss review of 


pwalker on PROD1PC71 with NOTICES